This story is part one in a four-part series about cell therapy created by the Fierce Biotech team. Gabrielle Masson, Helen Floersh, James Waldron and Max Bayer contributed reporting to this series.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results